Bosnian drug maker Bosnalijek's Q1 net loss narrows

Total revenue went up 33% year-on-year to 26.6 million marka, whereas total expenses rose 15.8% to 31.6 million marka in the January-March period, Bosnalijek said in a filing to the Sarajevo Stock Exchange (SASE) on Monday.

The company's shares last traded on SASE on April 24, closing 0.19% lower at 21.01 marka.

Bosnalijek is the largest pharmaceuticals company in Bosnia and Herzegovina.

(1 euro = 1.956 marka)